J. Hecht

发表

Metastasis in colorectal cancer: what makes the tumor aggressive?

J. Hecht, 2003, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers

Johannes G. Reiter, M. Nowak, K. Kinzler, 2012, Nature.

Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials

J. Berlin, J. Hecht, M. Peeters, 2007 .

Perioperative risks of bevacizumab and other biologic agents for hepatectomy: theoretical or evidence based?

J. Hecht, A. Bilchik, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of irinotecan in combination with amifostine in patients with advanced colorectal carcinoma

J. Hecht, D. Prager, L. Rosen, 2002, Cancer.

PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer.

J. Hecht, G. Fasola, J. Canon, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma

J. Hecht, G. Fasola, J. Canon, 2017, International Journal of Colorectal Disease.

Targeted lymph node evaluation in colorectal cancer: A decade of progress!

J. Hecht, A. Stojadinovic, Z. Wainberg, 2009, Journal of surgical oncology.

SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC).

J. Hecht, S. Dakhil, W. Go, 2013 .

2014 Final analysis of the PEAK trial: Overall survival (OS) and tumour responses during first-line treatment with mFOLFOX6 + either panitumumab (pmab) or bevacizumab (bev) in patients (pts) with metastatic colorectal carcinoma (mCRC)

J. Hecht, G. Fasola, J. Canon, 2015 .

First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab (pmab) or bevacizumab (bev) in wild-type (WT) RAS metastatic colorectal carcinoma (mCRC): Tumor response outcomes beyond RECIST.

J. Hecht, G. Fasola, J. Canon, 2015 .

Safety of panitumumab, a fully human monoclonal antibody against the epidermal growth factor receptor (EGFr), in patients (pts) with metastatic colorectal cancer (mCRC) across clinical trials

J. Berlin, J. Hecht, R. Amado, 2007 .

PD-014First-line treatment with modified FOLFOX6 (mFOLFOX6) + panitumumab or bevacizumab in patients with RAS/BRAF wild-type (WT) metastatic colorectal carcinoma (mCRC)

J. Hecht, G. Fasola, J. Canon, 2015 .

ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis

B. Wiens, J. Berlin, J. Hecht, 2004 .

ABX-EGF monotherapy in patients (pts) with metastatic colorectal cancer (mCRC): An updated analysis.

B. Wiens, J. Berlin, J. Hecht, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of Proton Pump Inhibitors and Capecitabine Efficacy in Advanced Gastroesophageal Cancer: Secondary Analysis of the TRIO-013/LOGiC Randomized Clinical Trial

J. Hecht, Y. Bang, M. Sawyer, 2017, JAMA oncology.

Prolonged nausea and vomiting after high dose chemotherapy and autologous peripheral stem cell transplantation in the treatment of high risk breast carcinoma

J. Hecht, L. Chap, T. Lembo, 1997, Cancer.

Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

J. Hecht, R. Salazar, E. Van Cutsem, 2012, The Lancet. Oncology.

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.

Daniel J. Freeman, J. Berlin, J. Hecht, 2008, Clinical colorectal cancer.

Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction

R. Elashoff, J. Hecht, Z. Wainberg, 2011, British Journal of Cancer.

A phase III randomized, open-label, controlled trial of chemotherapy and bevacizumab with or without panitumumab in the first-line treatment of patients with metastatic colorectal cancer.

J. Hecht, Z. Wainberg, 2006, Clinical colorectal cancer.

Extended RAS analysis for anti-epidermal growth factor therapy in patients with metastatic colorectal cancer.

J. Hecht, A. Grothey, S. Kopetz, 2015, Cancer treatment reviews.

Panitumumab in colorectal cancer

J. Hecht, Z. Wainberg, 2007, Expert review of anticancer therapy.

Phase II trial of everolimus in patients with refractory metastatic adenocarcinoma of the esophagus, gastroesophageal junction and stomach: possible role for predictive biomarkers

J. Hecht, H. Soares, Z. Wainberg, 2015, Cancer Chemotherapy and Pharmacology.

A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients.

J. Hecht, P. Philip, C. Takimoto, 2020 .

Panitumumab with irinotecan/leucovorin/5-fluorouracil for first-line treatment of metastatic colorectal cancer.

J. Berlin, J. Hecht, J. Posey, 2007, Clinical colorectal cancer.

Fecal and Tissue Microbiota Are Associated with Tumor T-Cell Infiltration and Mesenteric Lymph Node Involvement in Colorectal Cancer

Mary R. Kwaan, J. Hecht, Jonathan P. Jacobs, 2023, Nutrients.

Impact of geography on prognostic outcomes of 21,509 patients with metastatic colorectal cancer enrolled in clinical trials: an ARCAD database analysis

J. Hecht, C. Bokemeyer, E. Van Cutsem, 2021, Therapeutic advances in medical oncology.

Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

A. Carrato, J. Hecht, S. Raman, 2023, ESMO open.

Early predictors of improved long-term outcomes in first-line antiangiogenics plus chemotherapy (anti-ANG/CT) in metastatic colorectal cancer (mCRC): Analysis of individual patient (pt) data from the ARCAD database.

D. Sargent, M. Buyse, J. Hecht, 2014 .

A randomized phase II study of nivolumab monotherapy versus nivolumab combined with ipilimumab in advanced gastrointestinal stromal tumor (GIST).

J. Hecht, L. Rosen, M. Douek, 2019, Journal of Clinical Oncology.

Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer

J. Berlin, J. Hecht, A. Venook, 2007, Cancer.

Prognostic value of early objective tumor response (EOTR) to first-line systemic therapy in metastatic colorectal cancer (mCRC): Individual patient data (IPD) meta-analysis of randomized trials from the ARCAD database.

C. Tournigand, D. Sargent, J. Hecht, 2013 .

Low-dose trimetrexate glucuronate and protracted 5-fluorouracil infusion in previously untreated patients with advanced pancreatic cancer.

J. Hecht, L. Rosen, R. Amado, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

3014 (Presidential session, Tue 25 Sep 12.30–14.30) ORAL Association of somatic KRAS gene mutations and clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) receiving panitumumab monotherapy

Daniel J. Freeman, J. Berlin, J. Hecht, 2007 .

3458 Tolerability and efficacy of direct injection of pancreatic adenocarcinomas with onyx-015 under endoscopic ultrasound (eus) guidance.

J. Hecht, J. Hecht, S. Lahoti, 2000 .

Phase I and IIa studies of simtuzumab alone and in combination with FOLFIRI in patients with advanced solid tumors.

J. Hecht, A. Tolcher, P. LoRusso, 2014 .

A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal Cancer

Lindsay A. Renfro, Herbert I. Hurwitz, L. Diaz, 2017, Clinical Cancer Research.

Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

J. Hecht, F. Kabbinavar, J. Hamm, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer.

Seta Shahin, J. Hecht, J. Marshall, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.

J. Hecht, P. LoRusso, J. Hecht, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II trial of intravenous CI-1042 in patients with metastatic colorectal cancer.

J. Hecht, A. Benson, A. Shields, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CT colonography: value of scanning in both the supine and prone positions.

J R Hecht, J. Hecht, D. Lu, 1999, AJR. American journal of roentgenology.

A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.

J. Hecht, J. Hecht, W. Heim, 2010, Clinical colorectal cancer.

A Single Institution Experience in Compliance with Universal Screening for Lynch Syndrome in Colorectal Cancer

J. Hecht, C. Ko, J. Hecht, 2015, Journal of Gastrointestinal Surgery.

Cancer Management and Research Dovepress

J. Hecht, J. Hecht, E. Mitchell, 2022 .

Physical function and quality of life in frail and/or elderly patients with metastatic colorectal cancer treated with capecitabine and bevacizumab: an exploratory analysis.

J. Hecht, A. Naeim, J. Hecht, 2014, Journal of geriatric oncology.

Immunohistochemical evaluation of K-ras, p53, and HER-2/neu expression in hyperplastic, dysplastic, and carcinomatous lesions of the pancreas: evidence for multistep carcinogenesis.

J. Hecht, W. Grody, J. Hecht, 1999, Human pathology.

J. Hecht, W. Heim, M. Mo, 2010, Clinical colorectal cancer.

A new anti-CEA-SN-38 antibody-drug conjugate (ADC), IMMU-130, is active in controlling metastatic colorectal cancer (mCRC) in patients (pts) refractory or relapsing after irinotecan-containing chemotherapies: Initial results of a phase I/II study.

J. Berlin, J. Hecht, J. Marshall, 2015 .

Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone.

Daniel J. Freeman, J. Berlin, J. Hecht, 2008, Clinical colorectal cancer.

Phase 2/3, randomized, open-label study of an individualized neoantigen vaccine (self-amplifying mRNA and adenoviral vectors) plus immune checkpoint blockade as maintenance for patients with newly diagnosed metastatic colorectal cancer (GRANITE).

Brian A. Chauder, J. Hecht, H. Lenz, 2022, Journal of Clinical Oncology.